GW&K Investment Management LLC Increases Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

GW&K Investment Management LLC increased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 93.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 275,460 shares of the company's stock after purchasing an additional 133,379 shares during the quarter. Medpace makes up approximately 0.8% of GW&K Investment Management LLC's portfolio, making the stock its 18th biggest position. GW&K Investment Management LLC owned approximately 0.89% of Medpace worth $91,516,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Pallas Capital Advisors LLC lifted its holdings in shares of Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock valued at $1,086,000 after purchasing an additional 2,101 shares during the last quarter. Baillie Gifford & Co. increased its position in Medpace by 175.6% during the third quarter. Baillie Gifford & Co. now owns 14,876 shares of the company's stock worth $4,966,000 after buying an additional 9,478 shares during the period. Barclays PLC lifted its stake in Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company's stock valued at $6,603,000 after buying an additional 8,275 shares during the last quarter. CWA Asset Management Group LLC acquired a new stake in shares of Medpace in the third quarter valued at approximately $1,306,000. Finally, Oppenheimer Asset Management Inc. grew its position in shares of Medpace by 6.3% during the third quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company's stock worth $15,179,000 after acquiring an additional 2,675 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

Separately, Robert W. Baird upped their price target on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $381.44.

Medpace Stock Performance

Medpace stock traded up $4.96 during trading hours on Tuesday, reaching $324.13. 495,888 shares of the stock were exchanged, compared to its average volume of 297,809. The stock has a market cap of $9.88 billion, a P/E ratio of 25.66, a P/E/G ratio of 3.81 and a beta of 1.36. The firm's 50 day moving average is $342.26 and its 200 day moving average is $344.70. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.